Phosphorylation of the myosintargeting subunit 1 of myosin light chain phosphatase (MYPT1) plays an important role in the regulation of smooth muscle contraction, and several sites of phosphorylation by different protein Ser/Thr kinases have been identified. Furthermore, in some instances, phosphorylation at specific sites affects phosphorylation at neighboring sites, with functional consequences. Characterization of the complex phosphorylation of MYPT1 in tissue samples at rest and in response to contractile and relaxant stimuli is, therefore, challenging. We have exploited Phos-tag SDS-PAGE in combination with Western blotting using antibodies to MYPT1, including phosphospecific antibodies, to separate multiple phosphorylated MYPT1 species and quantify MYPT1 phosphorylation stoichiometry using purified, full-length recombinant MYPT1 phosphorylated by Rho-associated coiled-coil kinase (ROCK) and cAMP-dependent protein kinase (PKA sensitization via activation of the small GTPase RhoA and its downstream target Rho-associated coiled-coil kinase (ROCK) (46) and/or other kinases that phosphorylate the myosin-targeting subunit 1 of MLCP (MYPT1), resulting in reduced phosphatase activity and, therefore, increased LC 20 phosphorylation and force (20, 39, 55) , and 3) activating actin polymerization to enhance force transmission from the actin cytoskeleton to the extracellular matrix (58).
by PKA. Furthermore, phosphorylation at Thr 697 and Thr 855 by ROCK exposes two other sites of phosphorylation by PKA. Treatment of Triton-skinned rat caudal arterial smooth muscle strips with the membrane-impermeant phosphatase inhibitor microcystin or treatment of intact tissue with the membrane-permeant phosphatase inhibitor calyculin A induced slow, sustained contractions that correlated with phosphorylation of MYPT1 at 7 to Ն10 sites. Phos-tag SDS-PAGE thus provides a suitable and convenient method for analysis of the complex, multisite MYPT1 phosphorylation events involved in the regulation of myosin light chain phosphatase activity and smooth muscle contraction. smooth muscle; myosin light chain phosphatase; myosin-targeting subunit 1 of myosin light chain phosphatase; phosphorylation; Phostag SDS-PAGE VASCULAR SMOOTH MUSCLE CONTRACTION is regulated primarily by the reversible phosphorylation of myosin II at Ser 19 of the 20-kDa regulatory light chain (LC 20 ) (3). Phosphorylation is catalyzed by Ca 2ϩ /calmodulin-dependent myosin light chain kinase (MLCK) (24, 32) and dephosphorylation by myosin light chain phosphatase (MLCP) (19) . A variety of stimuli (including numerous circulating agonists such as angiotensin II, serotonin, endothelin-1, and norepinephrine; depolarization of the sarcolemma following neurotransmitter release; and an increase in intraluminal pressure) elicit vasoconstriction by 1) increasing cytosolic free Ca 2ϩ concentration ([Ca 2ϩ ] i ) to activate MLCK, 2) on a slower time scale, triggering Ca 2ϩ sensitization via activation of the small GTPase RhoA and its downstream target Rho-associated coiled-coil kinase (ROCK) (46) and/or other kinases that phosphorylate the myosin-targeting subunit 1 of MLCP (MYPT1), resulting in reduced phosphatase activity and, therefore, increased LC 20 phosphorylation and force (20, 39, 55) , and 3) activating actin polymerization to enhance force transmission from the actin cytoskeleton to the extracellular matrix (58) .
MLCP is a trimeric enzyme composed of PP1c␦ (the 38-kDa catalytic subunit, a type 1 protein Ser/Thr phosphatase), MYPT1 (115-130 kDa, which interacts with myosin and, thereby, targets the holoenzyme to its substrate), and M20 or M21 (20 kDa, of unknown function) (17, 19) . MLCP activity is regulated by phosphorylation, and MYPT1 has been shown to be phosphorylated in vitro at numerous sites by several protein Ser/Thr kinases [reviewed by Butler et al. (7) ]. ROCK phosphorylates MYPT1 at Thr 697 and Thr 855 [rat numbering is used throughout this article; National Center for Biotechnology Information (NCBI) accession no. XP_006241373] in vitro (16) , although in response to most relevant stimuli, phosphorylation by ROCK occurs in situ at Thr 855 (5, 7) . ROCK can also induce Ca 2ϩ sensitization via 1) phosphorylation of CPI-17 (PKC-potentiated inhibitory protein for PP1 of 17 kDa), which inhibits PP1c␦ directly (15) , and 2) induction of actin polymerization, probably via phosphorylation and activation of LIM kinase, leading to cofilin phosphorylation (38) .
There is some inconsistency in the literature concerning the sites in MYPT1 that are phosphorylated by cAMP-dependent protein kinase (PKA) and cGMP-dependent protein kinase (PKG) and the effects of cyclic nucleotide-mediated phosphorylation. Wooldridge et al. (61) (18) . While phosphorylation at each of the Thr residues decreased MLCP activity, phosphorylation at all four sites had no effect on MLCP activity, and prior phosphorylation at Thr 697 and Thr 855 by ROCK prevented the subsequent phosphorylation by PKA at Ser 696 and Ser 854 (18) . Consistent with these in vitro kinase assay results, treatment of rat caudal arterial smooth muscle with forskolin (which mimics ␤-adrenergic stimulation by activating adenylyl cyclase, leading to cAMP production) induced phosphorylation at (18) . Less is known about the other phosphorylation sites in MYPT1, which are discussed in more detail in DISCUSSION. An important advance in the analysis of complex phosphorylation events was the development of Mn 2ϩ -Phos-tag SDS-PAGE (27) , whereby a Mn 2ϩ -Phos tag (a dinuclear metal complex of 1,3-bis[bis(pyridin-2-ylmethyl)amino]propan-2-olate) covalently bound to polyacrylamide acts as a phosphatebinding moiety during SDS-PAGE and, thereby, captures phosphomonoester dianions such as phosphorylated Ser, Thr, and Tyr at alkaline pH (ϳ9). Phosphorylated and unphosphorylated forms of the protein are thereby separated by retarding the mobility of the phosphorylated species in the electric field. Moreover, the electrophoretic mobility is progressively retarded, the higher the phosphorylation stoichiometry, as exemplified by LC 20 phosphorylation at Thr 18 and Ser 19 (48, 56 20 , and this approach has been very useful in elucidating the functional effects of mono-vs. diphosphorylation and the occurrence of LC 20 diphosphorylation in response to physiological and pathophysiological stimuli (1, 2, 8, 9, 13, 14, 23, 36 -38, 48 -51, 57 (48) .
Mn 2ϩ -Phos-tag SDS-PAGE has been adapted to the analysis of phosphorylation of several proteins, e.g., ␣-and ␤-caseins, ovalbumin (27) , T cell antigen receptor subunits (11), the endoplasmic reticulum membrane proteins inositol-requiring enzyme-1␣ and protein kinase R-like endoplasmic reticulum kinase (63) , CPI-17 (13, 14, 21) , prostate-apoptosis response-4 (33), extracellular signal-regulated kinase 5 (43) , hybrid sensor kinases (31) , and huntingtin fragments (6) . We have found it necessary to adjust various parameters to optimize the separation of the different phosphorylated species for each protein of interest. In particular, the concentrations of Phos-tag reagent and Mn 2ϩ ions, as well as the acrylamide concentration and the acrylamide-to-bisacrylamide ratio and the current applied during electrophoresis, must be optimized. In general, success is easier to achieve with relatively low-molecular-mass phosphoproteins. However, by decreasing the concentration of Phos-tag reagent and reducing the current, phosphorylated forms of ϳ150-kDa proteins (the Fanconi anemia pathway protein FANCI) could be achieved (22) . Furthermore, separation of phosphorylated forms of high-molecular-mass proteins, e.g., mammalian target of rapamycin (289 kDa), ataxia telangiectasia-mutated kinase (350 kDa), p53-binding protein 1 (213 kDa), and epidermal growth factor receptor (180 kDa), has been achieved by use of low acrylamide concentrations and incorporation of agarose into the polyacrylamide gel (29, 30) .
Here we have adapted the Mn 2ϩ -Phos-tag SDS-PAGE technique to separate various phosphorylated forms of MYPT1 and used this approach to characterize MYPT1 phosphorylation in vascular smooth muscle tissue (rat caudal artery) treated with the phosphatase inhibitors microcystin (membrane-impermeant) and calyculin A (membrane-permeant). This approach also proved useful in identifying hierarchical phosphorylation events whereby phosphorylation at a specific site can prevent or enable phosphorylation at another site.
METHODS

Materials. [␥-
32 P]ATP was purchased from PerkinElmer (Woodbridge, ON, Canada) and microcystin-LR from Alexis Biochemicals (San Diego, CA). LC20 was purified from chicken gizzard as previously described (59) . The full-length clone of chicken MYPT1 (PPP1R12A, NCBI accession no. NP_990454.1) was generously provided by Dr. David J. Hartshorne (University of Arizona). PKA (the catalytic subunit of cAMP-dependent protein kinase) was purified to electrophoretic homogeneity from bovine heart as previously described (10) . Purified PKA (0.56 mg/ml) was stored at Ϫ80°C in 20 mM HEPES, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 0.02% sodium azide, 0.05% Triton X-100, and 25% glycerol and was not refrozen after thawing. Antibodies to LC 20 ; and 9) none of the phosphospecific antibodies crossreacted with unphosphorylated MYPT1. The Enhanced Chemiluminescence Kit was purchased from GE Healthcare (Piscataway, NJ). Constitutively active NH 2-terminal hexa-His-tagged and NH2-terminal hemagglutinin-tagged recombinant rat ROCK␣ (ROCK2; amino acids 2-543, 67.2 kDa), expressed by baculovirus in Sf21 insect cells, was purchased from EMD Millipore (catalog no. 14-338; specific activity ϭ 1,649 nmol P i·min Ϫ1 ·mg Ϫ1 ) with long S6 peptide substrate (30 M at 30°C and 100 M ATP). All other chemicals were reagent grade unless otherwise indicated and were obtained from Sigma or VWR (Mississauga, ON, Canada).
Expression and purification of recombinant GST-MYPT1. Fulllength GST-MYPT1 in pGEX-6P1 was expressed in Escherichia coli BL21(DE3)pLysS and purified as follows. Overnight seed cultures in Luria broth-ampicillin (5 ml) were added to flasks containing Luria broth-ampicillin (500 ml) and grown to an optical density of ϳ0.9 (ϳ3 h) at 37°C in a shaking incubator. Isopropyl ␤-D-1-thiogalactopyranoside was added to a final concentration of 0.2 mM, and protein expression was induced for 3 h prior to centrifugation at 8,000 rpm in a JA-10 rotor for 15 min. The supernatant was discarded, and 125 ml of 30 mM Tris·HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, and 0.2 mM DTT (buffer A) containing two cOmplete protease inhibitor tablets (catalog no. 05892791001, Roche) and 2 M diisopropylfluorophosphate were added to the pellet. Samples were frozen at Ϫ80°C in five 25-ml aliquots and thawed, and lysozyme (5 mg/25-ml aliquot) was added. After rotation at room temperature for 30 min, samples were centrifuged at 15,000 rpm in a JA-20 rotor for 15 min. The supernatant was diluted 1:3 in buffer A and loaded onto an SP-Sepharose column (1.5 ϫ 9 cm) previously equilibrated with buffer A. The column was washed with buffer A (ϳ100 ml) until absorbance at 280 nm returned to baseline, and bound protein was eluted from the column with a 160-ml salt gradient (0.15-0.5 M NaCl). Fractions were pooled on the basis of SDS-PAGE (10% acrylamide) minigels stained with Coomassie brilliant blue and loaded onto a glutathione-Sepharose column (1.5 ϫ 20 ml). Flow-through fractions were reapplied to the column, and this step was repeated a third time. The column was then washed first with buffer A containing 500 mM NaCl (60 ml) and then with buffer A containing 150 mM NaCl (60 ml). The bead slurry (40 ml) was recovered, 20 l of PreScission protease (catalog no. 27-0843-01, GE Healthcare) were added, and the slurry was rotated end-over-end at 4°C for ϳ60 h. Eluted fractions were recovered and analyzed by SDS-PAGE, and full-length MYPT1-containing fractions were pooled. Purity was assessed by SDS-PAGE with Coomassie brilliant blue staining (Fig.  1A) . The purified MYPT1 was free of kinase activity as shown by an in vitro kinase assay in the absence of exogenous kinase.
MYPT1 concentration measurement. The concentration of purified MYPT1 was determined by amino acid analysis at the Institute of Biomolecular Design (University of Alberta, Edmonton, AB, Canada) based on quantification of Arg, Ala, Pro, Val, Ile, Leu, and Phe following acid hydrolysis of purified, recombinant chicken MYPT1 (NCBI accession no. NP_990454) with a short NH2-terminal extension (Gly-Pro-Leu-Gly-Ser) before the initiating Met. Duplicate analyses gave protein concentrations of 95 and 97 g/ml (mean ϭ 96 g/ml). Full-length MYPT1 was stored at Ϫ80°C in 30 mM Tris·HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, and 0.2 mM DTT.
Kinase assays. Assay conditions were as follows: 25 mM Tris·HCl, pH 7.5, 5 mM MgCl 2, 5 mM EGTA, 0.073 g/ml ROCK or 1 or 10 g/ml PKA, 0.02 mg/ml MYPT1, and 0.5 mM [␥-
32 P]ATP (160 -250 cpm/pmol) at 30°C. Reactions were started by addition of radiolabeled ATP, and samples (20 l) were withdrawn at selected times, spotted onto P81 paper disks, and washed three times with 500 ml of 0.5% phosphoric acid and once with acetone. ROCK, PKA, or vehicle was added to the reaction mixture at 60.25 min (vertical arrow in Fig.  5A ), and samples (20 l) were withdrawn at selected times, spotted onto P81 paper disks, and washed as described above.
32 P incorporation was quantified by Č erenkov counting in a Beckman LS6000 scintillation counter and converted to moles of P i incorporated per mole of MYPT1 using the specific activity of the radiolabeled ATP (in cpm/pmol), and the amount of MYPT1 was counted (in mol). Values were corrected for nonspecific binding of the radiolabel: control time-course assays were carried out in the absence of all proteins or in the presence of MYPT1 but absence of kinases, both of which yielded low levels of " 32 P incorporation" that were not significantly different in the absence or presence of MYPT1. For SDS-PAGE and autoradiography, samples (20 l) were withdrawn and added to 20 l of 2ϫ SDS-gel sample buffer containing 2-mercaptoethanol, heated at 95°C for 2 min, and diluted 1:20 with SDS-gel sample buffer containing 2-mercaptoethanol before samples (20 l) were loaded on an SDS-gel (12.5% acrylamide). The same amount of MYPT1 (0.01 g) was loaded in each lane. Gels were stained with Coomassie blue and exposed to X-ray film as previously described (59) .
Tissue preparation and force measurements. Caudal arteries were removed from male Sprague-Dawley rats (200 -275 g body wt, 8 -12 wk of age) that had been anesthetized with halothane and euthanized according to protocols consistent with the standards of the Canadian Council on Animal Care and approved by the University of Calgary Animal Care and Use Committee. The arteries were cleaned of excess adventitia and adipose tissue in Ca 2ϩ -free HEPES-Tyrode (H-T) buffer (140.6 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.6 mM glucose, and 10 mM HEPES, pH 7.4). Segments were placed over a 0.31-mm needle and moved back and forth 40 times to remove the endothelium, cut into helical strips (1.5 ϫ 6 mm), mounted on an isometric force transducer (model FT03C, Grass Instruments) connected to a PowerLab (ADInstruments) eight-channel recording device with a resting tension of 0.45 g, and incubated for 20 min in H-T buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5.6 mM glucose, and 10 mM HEPES, pH 7.4) in a bath volume of 0.8 ml. Tissues were stimulated at least three times with H-T buffer containing 87 mM KCl (the increase in KCl concentration was balanced by a decrease in NaCl concentration) with a 20-min interval of relaxation in Ca 2ϩ -free H-T buffer between each contraction. Muscle strips were then incubated in Ca 2ϩ -free H-T buffer and either used for experiments with intact tissue or skinned (demembranated) by incubation for 5 min in buffer B {30 mM 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl-]amino]ethanesulfonic acid (TES), 0.5 mM DTT, 50 mM KCl, 5 mM K2EGTA, and 150 mM sucrose, pH 7.4} followed by 2 h in buffer B containing 1% (vol/vol) Triton X-100. Skinned tissues were washed (3 times for 5 min each) in pCa 9 solution (4 mM K2EGTA, 5.83 mM MgCl2, 0.5 mM dithioerythritol, 20 mM TES, pH 6.9, and an ATPregenerating system composed of 3.9 mM Na2ATP, 7.56 mM potassium propionate, 16.2 mM phosphocreatine, and 30 U/ml creatine kinase) and then incubated in pCa 9 or pCa 4.5 solution (4 mM CaEGTA, 5.66 mM MgCl2, 0.5 mM dithioerythritol, 20 mM TES, pH 6.9, and the ATP-regenerating system). Skinned tissues were treated with microcystin (1 M) in pCa 9 solution for the indicated times. Intact muscle strips were treated with calyculin A (0.5 M) in H-T buffer. At selected times of incubation with phosphatase inhibitors, tissues were immersed in cold 10% trichloroacetic acid, acetone, and 10 mM DTT, washed (3 times for 1 min each) with acetone and 10 mM DTT, and lyophilized for 36 h. Dried tissues were immersed in 1 ml of SDS-gel sample buffer [2% (wt/vol) SDS, 100 mM DTT, 10% (vol/vol) glycerol, 0.01% bromophenol blue, and 65 mM Tris·HCl, pH 6.8], heated to 95°C for 2 min, cooled to room temperature, and rotated overnight at 4°C. Samples (30 l) were subjected to SDS-PAGE (10% acrylamide) and Western blotting with anti-actin as previously described (35) . Scanning densitometry then enabled normalization of loading levels for subsequent Phos-tag SDS-PAGE.
Phos-tag SDS-PAGE. For analysis of MYPT1 phosphorylation, samples of tissue extracts in SDS-gel sample buffer containing identical amounts of actin (determined as described in Tissue preparation and force measurements) were subjected to phosphate affinity SDS-PAGE using an acrylamide-pendant phosphate-binding tag (Phos-tag SDS-PAGE). In an initial series of trials, the following parameters were changed systematically to identify the conditions that would achieve the most efficient separation of phosphorylated MYPT1 species: acrylamide concentration in the running gel, ratio of acrylamide to bisacrylamide, concentration of the Phos-tag reagent and of MnCl 2 in the running gel, current applied during electrophoresis, and presence or absence of SDS in the transfer buffer following Phos-tag SDS-PAGE (Table 1) . On the basis of the results of these trials, the following conditions were determined to be most effective and were Optimal conditions for separation of phosphorylated myosin-targeting subunit 1 of myosin light chain phosphatase (MYPT1) species were achieved by varying acrylamide concentration, acrylamide to-bisacrylamide ratio, and Phos-tag reagent and MnCl2 concentrations in the running gel, the current applied during electrophoresis, and the absence or presence of SDS in the transfer buffer for Western blotting. Optimal conditions are indicated in boldface.
ylenediamine. The resolving gel was composed of 6% (wt/vol) acrylamide, 0.11% (wt/vol) N,N=-methylenebisacrylamide (55:1 acrylamide-bisacrylamide), 30 M Phos-tag acrylamide (Waco Chemicals), 60 M MnCl 2, 0.1% (wt/vol) SDS, 375 mM Tris·HCl, pH 8.8, 0.05% (wt/vol) ammonium persulfate, and 0.07% (wt/vol) N,N,N=,N=-tetramethylethylenediamine. Electrophoresis was performed in 0.1% (wt/vol) SDS, 25 mM Tris, and 192 mM glycine at 15 mA per gel for 3.5 h in minigels, with the gel unit sitting in an ice bath. After electrophoresis, the gel was soaked in 2 mM EDTA, 25 mM Tris, and 192 mM glycine for 15 min and then in transfer buffer [25 mM Tris, 192 mM glycine, and 10% (vol/vol) methanol] for 15 min. Proteins were transferred to nitrocellulose membranes (0.2 m; Bio-Rad) overnight at 28 V and 4°C in 25 mM Tris·HCl, pH 7.5, 192 mM glycine, and 10% (vol/vol) methanol. Membranes were incubated with 5% (wt/vol) nonfat dry milk in Tris-buffered saline containing Tween [TBST: 20 mM Tris·HCl, pH 7.5, 137 mM NaCl, 3 mM KCl, and 0.05% (vol/vol) Tween 20] for 1-2 h and then in primary antibody in TBST for 2 h at room temperature. After washout of the primary antibody, membranes were incubated with secondary antibody (antirabbit IgG-horseradish peroxidase conjugate) in TBST at 1:5,000 dilution for 1 h at room temperature and washed with TBST (4 times for 5 min each) and then with TBS (once for 5 min) before chemiluminescence signal detection using the SuperSignal West Femto reagent (Thermo Scientific, Rockford, IL). The emitted light was detected and quantified with a chemiluminescence imaging analyzer (LAS3000mini, Fujifilm), and images were analyzed with MultiGauge version 3.0 software. The following primary antibodies were used: anti-pan-MYPT1 (1: For analysis of LC 20 phosphorylation, samples were resolved by Phos-tag SDS-PAGE and subjected to Western blotting as previously described (48) .
Data analysis. Values are means Ϯ SE; n indicates the number of animals used, and several muscle strips were used from each animal.
RESULTS
Purified, recombinant full-length MYPT1 (Fig. 1A) was phosphorylated by ROCK to a stoichiometry of ϳ2 mol P i /mol MYPT1, as determined by quantification of 32 P incorporation (Fig. 1B) . As predicted, three forms of MYPT1, corresponding to unphosphorylated, monophosphorylated, and diphosphory- A: purified, recombinant full-length MYPT1 was incubated with the catalytic subunit of PKA (10 g/ml; see METHODS). Reactions were started at time 0 by addition of [␥-32 P]ATP, and samples of reaction mixtures were withdrawn at the indicated times for quantification of 32 P incorporation. Values are means Ϯ SE (n ϭ 3-4). Inset: samples withdrawn at the indicated times were subjected to Phos-tag SDS-PAGE and Western blotting with anti-MYPT1. B: samples withdrawn at the indicated times were subjected to SDS-PAGE and Coomassie blue staining (left) and autoradiography to detect incorporated 32 P (pMYPT1; right). M, molecular mass marker. lated MYPT1, were separated by Phos-tag SDS-PAGE (Fig.  1B, inset) . The Coomassie blue-stained regular SDS gel and autoradiogram in Fig. 1C confirm extensive 32 P incorporation into MYPT1. Western blotting with phosphospecific antibodies confirmed phosphorylation by ROCK at the predicted sites of MYPT1, i.e., Thr 697 and Thr 855 , and indicated that the rates of phosphorylation at the two sites were similar (Fig. 1D) . No phosphorylation at Ser 696 or Ser 854 was detected using phosphospecific antibodies (data not shown).
MYPT1 was phosphorylated to a stoichiometry of ϳ4 mol P i /mol by PKA, as determined by quantification of 32 P incorporation ( Fig. 2A) . Consistent with this observation, Phos-tag SDS-PAGE separated five forms of MYPT1 corresponding to the protein phosphorylated at zero to four sites ( Fig. 2A, inset) (Fig. 2B) , as shown previously by regular SDS-PAGE and Western blotting in conjunction with site-specific mutagenesis of Ser/Thr to Ala (18) . If a 10-fold-higher concentration of PKA was used to phosphorylate MYPT1, a stoichiometry of ϳ9 mol P i /mol MYPT1 was achieved, as determined by quantification of 32 P incorporation (Fig. 3A) . The Coomassie blue-stained regular SDS gel and autoradiogram in Fig. 3B confirm 32 P incorporation exclusively into MYPT1. While of unlikely physiological relevance, given the high PKA concentration used in this experiment, the ability to achieve high phosphorylation stoichiometry was useful in assessing the ability of Phos-tag SDS-PAGE to separate multiple phosphorylated forms of the protein (Fig. 3A,  inset, and Fig. 4 (Fig.  4) , as previously demonstrated (18) . It is evident in Fig. 4 combination of ROCK and PKA evoked rapid phosphorylation to a stoichiometry of ϳ4 mol P i /mol MYPT1, as determined by quantification of 32 P incorporation (Fig. 5A) . PKA alone elicited phosphorylation to similar stoichiometry, but at a slower rate, and ROCK alone phosphorylated MYPT1 at two sites, as shown in Fig. 1 Fig. 1C) , PKA was capable of phosphorylating MYPT1 at two additional sites (i.e., to ϳ4 mol P i /mol MYPT1) (Fig. 5A) (18) . We then tested the applicability of Phos-tag SDS-PAGE to characterize MYPT1 phosphorylation in tissue samples. Figure  6A illustrates a typical slow, sustained contractile response to treatment of Triton-skinned rat caudal arterial smooth muscle strips with the membrane-impermeant type 1 and 2A phosphatase inhibitor microcystin at pCa 9. This was accompanied by phosphorylation of LC 20 at Thr 18 and Ser 19 ( Fig. 6B) , as previously shown (48) . Phos-tag SDS-PAGE was used to examine MYPT1 phosphorylation in the same tissue samples (Fig. 6C) . Triton-skinned tissues maintained at resting tension in the absence (pCa 9) or presence (pCa 4.5) of Ca 2ϩ exhibited a low basal level of MYPT1 phosphorylation, which increased progressively upon exposure to microcystin. At least seven species of MYPT1 could be separated in this way.
Separation of phosphorylated forms of a protein by Phos-tag SDS-PAGE requires the presence of Mn 2ϩ in the running gel (29) . As shown in Fig. 6D , if MnCl 2 was omitted from the running gel and divalent cations were chelated with EDTA, all MYPT1 species migrated as a single band. We can, therefore, conclude with confidence that the more slowly migrating bands observed in the presence of Mn 2ϩ (Fig. 6D ) are indeed phosphorylated forms of MYPT1, and the greater the reduction in mobility, the more sites are phosphorylated.
Finally, we used the membrane-permeant phosphatase inhibitor calyculin A to induce a slow, sustained contraction of intact rat caudal arterial smooth muscle (Fig. 7A) , which was again accompanied by phosphorylation of LC 20 at Thr 18 and Ser 19 ( Fig. 7B) , as previously demonstrated (48) . Phos-tag SDS-PAGE comparison with unphosphorylated recombinant MYPT1 (Fig. 7C, lane 1 ) indicated significant phosphorylation of MYPT1 in tissue under resting tension in the absence or presence of Ca 2ϩ (Fig. 7C, lanes 2 and 3, respectively) . There appears to be a higher stoichiometry of phosphorylation in the presence of extracellular Ca 2ϩ , and this was confirmed in six independent experiments suggesting that a Ca 2ϩ -dependent kinase is capable of phosphorylating MYPT1. Calyculin A-induced contraction correlated with the appearance of several more highly phosphorylated forms of MYPT1 until a stably phosphorylated MYPT1 with stoichiometry Ն10 mol P i /mol MYPT1 was observed at the plateau of force development (Figs. 7C and Fig. 4) . Figure 7D confirms that phosphorylation stoichiometry is higher for intact rat caudal arterial smooth muscle strips treated with calyculin A than for Triton-skinned tissue treated with microcystin, suggesting that a kinase(s) capable of phosphorylating MYPT1 in situ is lost following demembranation. This observation may be useful in identifying novel kinases that phosphorylate MYPT1 in situ. Analysis of the time course of phosphorylation of MYPT1 in intact tissue in response to calyculin A treatment by Western blotting with phosphospecific antibodies following Phos-tag SDS-PAGE revealed phosphorylation at Thr 855 , which is partially phosphorylated under resting conditions, first, followed by Fig. 6 . Microcystin-induced phosphorylation of 20-kDa regulatory light chain of smooth muscle myosin (LC20) and MYPT1 in skinned rat caudal arterial smooth muscle. A: after control pCa 4.5-induced contractions (the last of which is shown) and relaxation at pCa 9, Triton-skinned rat caudal arterial smooth muscle strips were treated with 1 M microcystin at pCa 9 and force was recorded continuously. B and C: skinned smooth muscle strips incubated in the presence (pCa 4.5) or absence (pCa 9) of Ca 2ϩ or treated with 1 M microcystin (MC) at pCa 9 for the indicated times (arrows in A) were subjected to Phos-tag SDS-PAGE and Western blotting (IB) with anti-LC20 or anti-MYPT1. Unphosphorylated, monophosphorylated, and diphosphorylated LC20 species are labeled 0P-LC20, 1P-LC20, and 2P-LC20, respectively. Unphosphorylated, recombinant full-length MYPT1 (0P-MYPT1) indicates migration of the unphosphorylated protein for comparison. Maximally phosphorylated MYPT1 is also labeled (maxP-MYPT1). D: Triton-skinned rat caudal arterial smooth muscle strips were incubated in the absence of Ca 2ϩ (pCa 9) or treated with microcystin at pCa 9 for the indicated times prior to Phostag SDS-PAGE in the presence of MnCl2 or EDTA and Western blotting with anti-MYPT1. Data are representative of 5 (B), 3 (C), and 4 (D) independent experiments. phosphorylation at Ser 696 and Ser 854 (Fig. 7E ). Phosphorylation at Thr 697 is robust under resting conditions and does not increase in response to calyculin A (Fig. 7E) , as we observed previously using regular SDS-PAGE and Western blotting with anti-phosphorylated (Thr 697 ) MYPT1 (see Fig. 4 , A and C, in (18), these findings suggest that another kinase, which is distinct from PKA and whose activity is unmasked by phosphatase inhibition, is capable of phosphor- (62) . In most instances, the functional consequences of these phosphorylation events are unknown. It is, therefore, essential to develop novel strategies for the characterization of such complex phosphorylation events. Here we demonstrate the power of Phostag SDS-PAGE to separate MYPT1 species with 0 to Ն10 phosphorylated residues.
Estimates of MYPT1 phosphorylation stoichiometry at Thr 697 and Thr 855 have previously been made in bladder smooth muscle by Western blotting with phosphospecific antibodies and comparison with MYPT1 phosphorylated stoichiometrically at these sites in response to calyculin A treatment. The latter was verified by comparison with a recombinant fragment of human MYPT1 [GST-MYPT1-(654 -880)] phosphorylated to 2 mol P i /mol MYPT1 by ROCK (54) . Similarly, Dimopoulos et al. (12) estimated the stoichiometry of phosphorylation of MYPT1 at Thr 855 in resting femoral arterial smooth muscle and following stimulation with phenylephrine using known amounts of phosphorylated recombinant MYPT1 as a standard in Western blotting with anti-phosphorylated (Thr 855 ) MYPT1. Phos-tag SDS-PAGE offers an alternative approach for determination of MYPT1 phosphorylation stoichiometry that does not require purified phosphorylated protein for standardization.
An often overlooked limitation of the use of phosphospecific antibodies is the effect of phosphorylation at a neighboring or nearby site on its affinity for a particular phosphospecific antibody. This is exemplified by two of the phosphospecific antibodies used in this study: anti-phosphorylated (Ser 696 ) MYPT1 and anti-phosphorylated (Ser 696/854 ) MYPT1. It is evident from Fig. 4 (Fig. 2B) . It is, therefore, extremely important to characterize phosphospecific antibodies very carefully, particularly when the substrate is known to be phosphorylated at multiple sites; otherwise, erroneous conclusions may be drawn.
We previously observed that phosphorylation of truncated MYPT1 (corresponding to residues 667-1004 of the chicken protein) by ROCK (at the sites equivalent to Thr 697 and Thr 855 of rat MYPT1) prevented subsequent phosphorylation at the neighboring Ser 696 and Ser 854 sites (18) . We observed, nevertheless, that PKA was capable of inducing additional phosphorylation (ϳ2 mol P i /mol MYPT1) after ROCK had phosphorylated Thr 697 and Thr 855 stoichiometrically (Fig. 5) , suggesting that ROCK-mediated phosphorylation at Thr 697 and Thr 855 not only prevents phosphorylation by PKA at the neighboring Ser 696 and Ser 854 but also exposes two new phosphorylation sites to PKA. PKA consensus sequences were identified in chicken MYPT1 by Scansite 3 (44) and are listed in Table 2 with the corresponding sequences of rat MYPT1. Twelve of the 14 consensus sequences identified in chicken MYPT1 are conserved in the rat and include the fully conserved PKA sequence around the Ser 669 phosphorylation site (rat numbering) identified by Yuen et al. (64) .
In summary, we describe here a modification of the technique of Phos-tag SDS-PAGE that allows the separation of multiple phosphorylated forms of MYPT1, enabling identification of the number of phosphorylated sites and the overall phosphorylation stoichiometry under defined conditions in vitro and ex vivo. When used in conjunction with Western blotting using well-characterized phosphospecific antibodies, this approach can yield important information regarding sequential and hierarchical phosphorylation events in the regulation of smooth muscle contraction. 
